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With the expiration of patents on the ﬁrst generation of rDNA biopharmaceuticals, competitors began to
introduce biosimilar products. The concept of generics as applied to classical chemical drugs cannot be
used for biotechnology products. Physicochemical characterization, bioassays and animal studies do not
have the ability to predict reliably the safety and efﬁcacy of biotherapeutics. Clinical studies are always
necessary. While regulators all over the world were really in need of a comprehensive guideline in this
area, WHO introduced a guideline which is principally a basis for regulating biosimilars and is applicable
in Iran, as well as many other countries.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
During the past ﬁve decades, many biological products such as
human plasma derived products, anti-toxins and animal origin
products like insulin came to the market. Although these products
had many beneﬁts, some were also associated with adverse events
following administration to patients, such as transmission of
infectious diseases by plasma derived products, transmission of CJD
by human growth hormone derived from the pituitary glands of
cadavers, and sensitivity to animal insulin.
Since the 1970s, when rDNA technology was focused on devel-
oping products with a reduced or eliminated risk of adverse events,
many biological and medicinal proteins have been produced and
launched. Human insulin was the ﬁrst one to be developed by Elli
Lilly in 1982. Today, many of these medicinal products have been
developed and are available on the worldwide market.
Several years before the beginning of the expiration of the
patent and the exclusivity of some blockbusters such as human
growth hormone, a number of companies including several generic
manufacturers have been engaged in the development and
production of subsequent versions of these products. It was the
time when many controversial scientiﬁc challenges for marketing
authorization of generic recombinant products were raised by
innovator brand producers. These discussions indicated that unlikeCouncil Secretariat, Pharma-
nization, Ministry of Health,
ehran, Iran. Tel.: þ98 21 8892
nd@fdo.ir (N. Hadavand).
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generally exhibited high molecular complexity, and are sensitive to
manufacturing process differences. Furthermore, the follow-on
manufacturer does not have access to the data on originator’s cell
bank, fermentation, puriﬁcation processes and impurities, which is
difﬁcult to make a comparison with an innovator product. It was
recognized that small differences in the follow-on product can have
signiﬁcant and serious health implications. Due to these consider-
ations, regulatory authorities have faced difﬁculties in decision
making regarding the licensing of “Biogeneric” products, for which
other terms including “Biosimilars”, “Follow-on biologics” and
“Subsequent entry biologics” have emerged to describe ofﬁcially-
approved subsequent versions of innovator biopharmaceutical
products made by a different manufacturers following patent
expiration of innovator products.
The EuropeanMedicines Agency (EMEA) was the ﬁrst regulatory
authority to specially adapt its approval procedure to authorize
subsequent versions of previously approved biologics, which are
termed “similar biological medicinal products” or for short, often
called biosimilars. This procedure is based on a thorough demon-
stration of “comparability” of the “similar” product to an existing
approved product. Guidelines for production, characterization, pre-
clinical and clinical studies and registration of these products have
been issued [1]. The World Health Organization (WHO) also got
involved and issued draft of Guidelines on Evaluation of Similar
Biotherapeutics (SBPs). These were ﬁnalized on October 2009 [2].
Based on WHO guidelines, some regulatory authorities such as
Malaysia, Singapore, Republic of Korea, Turkey, Saudi Arabia, Japan,
Brazil, South Africa, Jordan, Mexico and Iran [3e6] have prepared
guidelines for registration of these medicinal products.Organization has granted the Publisher permission for the reproduction of this article.
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In the Islamic Republic of Iran (I.R.IRAN) all medicinal products
must be regulated by the National Regulatory Authority (NRA)
which is working under the umbrella of the Ministry of Health and
Medical Education (MOH) as the governmental body. According to
the laws, the MOH is responsible for establishing quality standards
for regulation of all medicinal products.)Law of “Duties and
responsibilities of Ministry of Health and Medical Education”, 1985
and amendment on 1988(.The ofﬁcial name of the NRA in Iran is the
Division of Pharmaceuticals and Narcotic Affairs. Other divisions of
theMOHwhich are also involved inmedicinal products registration
consist of the Food and Drug Control Laboratory (FDCL), the ADR
Centre, Clinical Trials Evaluation Committee (CTC) and the Centre
for Diseases Control (CDC). The Division of Pharmaceutical and
Narcotic Affairs is composed of several ofﬁces for the regulation of
medicines, biologics, herbal products, controlled substances and
medical devices. The ofﬁce of biologics in collaboration with FDCL
and ADR Centre is responsible for the marketing authorization and
licensing, lot release and regulatory inspections of biologics prod-
ucts. In fact, the ofﬁce of Biologics initiated its activity a few years
ago, in 2001. The system was strengthened by implementation of
a quality system through development of a quality manual and
other relevant documents including guidelines and standard
operating procedures as well as check-lists. Training was provided
to the staff through collaboration with the World Health Organi-
zation (WHO). Several in country and foreign training activities
were conducted in order to build up regulatory capacity.
For more speciﬁc and efﬁcient activity, the personnel of bio-
logics ofﬁce work in different sub-divisions including vaccines,
human plasma derived products, cell therapy and tissue engi-
neering and recombinant products. The sub-division of recombi-
nant products is responsible for the marketing authorization,
licensing, lot release and regulatory inspection of recombinant
proteins and monoclonal antibodies (mAbs). Also, each sub-
division is responsible for the preparation and adoption of neces-
sary instructions, guidelines and other related documents which
will ﬁnally be approved by the DeputyMinister for food and drug or
the General Director of Pharmaceutical and narcotic affairs.
Until 2002, there were no speciﬁc instructions or guidelines for
production and registration of biological medicinal products, nor
recombinant proteins. All the relevant documents have been
prepared in the period of 2002e2010.
3. Products licensed and under consideration
Like many other countries, in the early part of the last century,
the ﬁrst generation of vaccines that was used in Iran were the ﬁrst
biological medicinal products. Later on, many products such as
Insulin, Somatropin, Granulocyte Colony Stimulating Factor (GCSF)
and Interferons were registered based on regulation for generic
products. The registration process was not the same for all of these
products, because while the NRA received each application, the
experts evaluated information from other regulatory agencies, like
EMEA and WHO, and made decisions on a case by case basis.
The progress and maturation of the decision making process is
obvious throughout this period. For example, for the ﬁrst applica-
tion the NRA requested amino acid sequence analysis, accelerated
stability tests and data from acute toxicity studies in animals. For
the subsequent applications data like N-terminal sequencing, the
biological activity, stress stability tests, repeated dose toxicity and
clinical studies were requested. Clinical studies requested for the
ﬁrst products were conducted and approved without a comparator.
Since 2006, a small sample size of a double blind controlled clinical
trial using the original brand as comparator has become obligatory.For the purpose of registration of recent applications, the immu-
nogenicity and pharmacovigilance were requested as well. In fact,
since 2007, the Iran NRA tried to register SBPs according to WHO
draft guideline.
With establishment of the Biologics Ofﬁce within the NRA and
with the support of WHO during vaccine/biologics regulatory
system project, supported by a loan from the World Bank and in
which the WHO played its role as executing agency in providing
international consultants and educational courses [7], all necessary
documents including instructions and guidelines were prepared of
which a few were applicable for SBPs as well.
Since year 2003, about 6 local non-innovator copy products have
been produced, registered and launched on the Iran market
including Erythropoetine alfa, Erythropoietin beta, Interferon alfa,
Interferon beta- 1a, Somatropin and GCSF. About another 16
requests have been submitted and are under evaluation at different
steps as previously mentioned according to WHO draft guideline.
4. The guideline on marketing authorization of biosimilars in
Iran
Following close cooperation with WHO over the past decade,
the Iran NRA prepared a draft guideline on the registration of
biosimilars based on the WHO draft guideline of 2009. This was
revised in two steps based on WHO draft guideline changes. It has
been ﬁnalized and approved in September 2010 by the Iran expert
committee on biologicals and as the last step approved by the Head
of the Iran FDA in February 2011. After its issuance, there will be
a six month time limit for manufacturers to implement the
guideline. The guideline will not apply to previously registered
products.
The framework of the guideline is very similar to the WHO
guideline and consists of the following sections:
a) Introduction and Scope: deﬁnition of biosimilars, original
brand, registration process and general consideration
b) Quality: production process, characterization( physiochemical,
biological activity, immunochemical, accelerated stability test),
speciﬁcations, analytical techniques, stability
c) Non clinical evaluation
d) Clinical evaluation: pharmacokinetic studies, conﬁrmatory
pharmacokinetic/pharmacodynamic studies, efﬁcacy studies,
safety and immunogenicity
e) Pharmacovigilance
f) Prescription and labeling information5. Similarities and differences between biosimilars
registration guideline in Iran in comparison with WHO
guideline
Iran requires a full head to head comparative study of a new
follow-on product vs. a Reference Biological Product in the quality,
non-clinical and clinical characteristics as stated in the published
2009 WHO guideline.
5.1. Similarities
1. In Iran, there is a requirement for a head to head comparison of
a SBP to a reference product in quality, non-clinical and clinical
attributes in exactly the same way as in the ﬁnal adopted
version of the WHO Guidelines.
2. As in the WHO guideline, the regulatory body believes that
pharmacopoeial monographs provide only a minimum set of
requirements for a particular product and additional test
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documents relating to the RBP available to the NRA.
3. According to the Iran guideline, the drug substance and
ﬁnished product of the RBP and SBP must be shown to be
similar. This is exactly the same to WHO guideline in terms of
quality.
4. According to WHO and Iran regulatory opinion, the dosage
form and route of administration should be the same of SBP as
that of RBP.5.2. Differences
1. According to WHO Guidelines, the RBP should be a product
licensed on a full quality, safety and efﬁcacy data package.
Usually, an SBP should not be considered as a choice for an RBP.
However, in the I.R. Iran, there are instances where the original
brand has not been registered and indeed may never be since
the RBP producer has no intention of doing so. Nevertheless,
there is a need to register products made in Iran. In such cases,
the Iran guidelines allow a local producer to evaluate an SBP
produced in Iran in a head to head comparison to a reference
product consisting of an SBP with FDA or EMEA approval and
accessible PSUR and which has already been licensed in Iran
and marketed for a suitable period of time.
2. After registration and the provision of sufﬁcient data on
consistency of production, one characterized batch of this
similar product may be used as a reference for quality control
tests for batch release. This approach does not exist in theWHO
guideline.
3. According to the WHO, guideline speciﬁcations for a SBP may
not be the same as for the RBP, since the manufacturing
processes will be different and different analytical procedures
and laboratories will be used for the assays. But in Iran, spec-
iﬁcations for a SBP should be the same as for the reference
product or meet pharmacopoeial speciﬁcations.
4. According to the WHO guideline, head-to-head accelerated
stability studies comparing the SBP to the RBP will be of value
in determining the similarity of the products by showing
comparable degradation proﬁles. Based on Iran regulations, an
accelerated stability study is required as an important element
in determination of similarity between a SBP and a RBP but ithas not been required for this study to be in a head to head
style.6. Conclusion
Access to biotherapeutics of assured quality, safety and efﬁcacy
at more affordable prices is the concern of regulatory bodies all
over the world. WHO has drafted a guideline to clarify issues
related to similar biotherapeutic products which was ﬁnalized on
October 2009 as a guide to countries seeking scientiﬁc advice on
this matter.
As a producing country for biotherapeutics, Iran based its
increasing need and ﬁnalized its own guideline on biosimilars in
February 2011. The WHO guideline was used as a rich scientiﬁc
basis for the preparation of this guideline. However, there have
been some modiﬁcations to deal with country speciﬁc needs.
The evaluation of a biosimilar product is to be conducted based
on a head to head comparison of SBP to a reference product but
instead of using a RBP with full quality, safety, and efﬁcacy data,
a SBP with EMEA or FDA approval and accessible PSUR, which has
been licensed in Iran and marketed for a suitable duration of time,
can be used as a reference product by local biosimilar producers.
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